ImmunityBio, Inc.

ImmunityBio Inc's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, ImmunityBio Inc has 1.05B shares outstanding.

As of June 30, 2026, ImmunityBio Inc maintains a current ratio of 5.72, meaning it holds 5.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -77.75, indicating conservative leverage, while an interest coverage ratio of -2.05 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -192.58, reflecting losses generated across the asset base. The company generates approximately 210,850.33 in revenue per employee across its workforce of 688.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.26 indicates how many times ImmunityBio Inc sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, ImmunityBio Inc recorded an income tax benefit of -140,923.30 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -868.81M and -868.61M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, ImmunityBio Inc generated 145.12M in revenue and converted that into -868.61M in net income, yielding earnings per share of -0.87. EBITDA reached -205.87M, while operating income came in at -220.40M.

As of June 30, 2026, ImmunityBio Inc holds 312.81M in cash and equivalents against 711.67M in total debt, resulting in a net debt position of 611.55M. Total book value stands at -916.11M, with working capital of 317.08M providing operational flexibility.

ImmunityBio Inc produced -246.08M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -6.46M in capital expenditures, free cash flow totaled -252.54M - equivalent to -0.25 per share.

Over the twelve months ended June 30, 2026, ImmunityBio Inc posted a gross margin of 99.34, reflecting its pricing power and cost economics. The operating margin of -151.88 and net profit margin of -598.56 provide insight into operational efficiency.